Martine Rothblatt Sells 75 Shares of United Therapeutics (NASDAQ:UTHR) Stock

Key Points

• CEO Martine Rothblatt sold 75 shares of United Therapeutics on March 13 at an average price of $536.95 for $40,271, a 0.02% reduction leaving her with 324,443 shares valued at about $174.2 million.
• Quarterly results showed EPS of $7.70, beating estimates by $0.92, while revenue of $790.2 million missed consensus, though revenue was up 7.4% year-over-year.
• The stock is trading near recent highs (around $580.51) and analysts have raised price targets; the consensus rating is "Moderate Buy" with an average target of $601.50.

United Therapeutics Corporation (NASDAQ:UTHR - Get Free Report) CEO Martine Rothblatt sold 75 shares of United Therapeutics stock in a transaction that occurred on Friday, March 13th. The shares were sold at an average price of $536.95, for a total transaction of $40,271.25. Following the sale, the chief executive officer owned 324,443 shares of the company's stock, valued at approximately $174,209,668.85. The trade was a 0.02% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website.

United Therapeutics Stock Up 0.5%

Shares of UTHR traded up $2.93 during mid-day trading on Thursday, reaching $580.51. 446,676 shares of the company's stock were exchanged, compared to its average volume of 497,137. United Therapeutics Corporation has a 52-week low of $272.12 and a 52-week high of $607.89. The company has a market cap of $25.44 billion, a price-to-earnings ratio of 20.81, a PEG ratio of 1.65 and a beta of 0.75. The company has a 50-day simple moving average of $522.64 and a two-hundred day simple moving average of $487.71.

United Therapeutics (NASDAQ:UTHR - Get Free Report) last issued its quarterly earnings data on Wednesday, February 25th. The biotechnology company reported $7.70 earnings per share (EPS) for the quarter, topping the consensus estimate of $6.78 by $0.92. United Therapeutics had a return on equity of 19.30% and a net margin of 41.94%.The firm had revenue of $790.20 million during the quarter, compared to the consensus estimate of $814.80 million. During the same period in the previous year, the firm posted $6.19 EPS. The company's quarterly revenue was up 7.4% compared to the same quarter last year. As a group, equities research analysts predict that United Therapeutics Corporation will post 24.48 EPS for the current fiscal year.

Analyst Ratings Changes

UTHR has been the subject of a number of recent research reports. Raymond James Financial initiated coverage on United Therapeutics in a research report on Friday, April 10th. They set an "outperform" rating and a $700.00 price objective for the company. Oppenheimer lifted their price objective on United Therapeutics from $575.00 to $600.00 and gave the stock an "outperform" rating in a research report on Thursday, February 26th. UBS Group lifted their price objective on United Therapeutics from $655.00 to $705.00 and gave the stock a "buy" rating in a research report on Thursday, March 5th. Weiss Ratings reiterated a "buy (b)" rating on shares of United Therapeutics in a research report on Monday, December 29th. Finally, Bank of America lifted their price objective on United Therapeutics from $569.00 to $626.00 and gave the stock a "neutral" rating in a research report on Tuesday, March 31st. Ten research analysts have rated the stock with a Buy rating and three have assigned a Hold rating to the company's stock. According to data from MarketBeat.com, the company presently has a consensus rating of "Moderate Buy" and an average target price of $601.50.

Institutional Trading of United Therapeutics

Hedge funds and other institutional investors have recently bought and sold shares of the company. Torren Management LLC purchased a new stake in United Therapeutics in the 4th quarter worth approximately $26,000. Activest Wealth Management grew its stake in United Therapeutics by 1,400.0% in the 4th quarter. Activest Wealth Management now owns 60 shares of the biotechnology company's stock worth $29,000 after acquiring an additional 56 shares during the period. Entrust Financial LLC purchased a new stake in United Therapeutics in the 4th quarter worth approximately $31,000. Wilmington Savings Fund Society FSB grew its stake in United Therapeutics by 125.6% in the 3rd quarter. Wilmington Savings Fund Society FSB now owns 88 shares of the biotechnology company's stock worth $37,000 after acquiring an additional 49 shares during the period. Finally, Harbor Capital Advisors Inc. purchased a new stake in United Therapeutics in the 4th quarter worth approximately $48,000. 94.08% of the stock is owned by hedge funds and other institutional investors.

United Therapeutics Company Profile

United Therapeutics Corporation NASDAQ: UTHR is a biotechnology company dedicated to the development and commercialization of unique products to address life-threatening illnesses. The company's primary focus has been on pulmonary arterial hypertension (PAH), where it has launched several therapies designed to improve functional capacity and quality of life for patients. Its marketed products include continuous infusion treprostinil (Remodulin), inhaled treprostinil (Tyvaso), oral treprostinil (Orenitram) and tadalafil (Adcirca), each tailored to different modes of administration and patient needs.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.